logo
logo

Vergent Bioscience announced it raised $3.75 Million in an initial filing from an offering of $5 Million

Feb 18, 20255 months ago

Amount Raised

$3.75 Million

MinneapolisBiotechnology

Company Information

Company

Vergent Bioscience

Location

5810 W 78TH ST

Minneapolis, Minnesota, United States

About

Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors. Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

Related People